ICM
EXEL icon

Invenomic Capital Management’s Exelixis EXEL Stock Holding History

Invenomic Capital Management’s Portfolio EXEL Stock Details EXEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-460,514
Closed -$10.3M – 154
2024
Q2 		$10.3M Buy
+460,514
New +$10.2M 0.5% 68
2023
Q4 		– Sell
-526,458
Closed -$11.5M – 186
2023
Q3 		$11.5M Sell
526,458
-236,992
-31% -$4.96M 0.48% 65
2023
Q2 		$14.6M Sell
763,450
-629,259
-45% -$12.1M 0.74% 44
2023
Q1 		$27M Buy
1,392,709
+428,622
+44% +$7.47M 1.53% 18
2022
Q4 		$15.5M Buy
+964,087
New +$15.7M 1.05% 30

Other funds holding EXEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invenomic Capital Management's EXEL Position: Q3 2024 in Review

Invenomic Capital Management sold out of Exelixis (EXEL) in Q3 2024, closing a stake of 460,514 shares — an estimated $10.3M sold.

Invenomic Capital Management first reported a position in EXEL in Q4 2022 and held it in 5 quarters. The position peaked at $27M in Q1 2023. 452 funds tracked by Wall St. Rank hold EXEL as of Q3 2024.

  • Invenomic Capital Management reported no remaining Exelixis position as of Q3 2024 after selling out during the quarter.
  • Invenomic Capital Management sold 460,514 Exelixis shares in Q3 2024, an estimated $10.3M.
  • Invenomic Capital Management first reported a position in Exelixis in Q4 2022 and held it in 5 quarters.
  • Invenomic Capital Management's Exelixis position peaked at $27M in Q1 2023.
  • 452 funds tracked by Wall St. Rank held Exelixis as of Q3 2024.

Based on Invenomic Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.